LEAF-4L6715.

Proprietary Liposomal Transcrocetin

for Hypoxia-Related Disorders

  • Our Mission

    We are on a mission to discover, develop, manufacture and commercialize innovative medicines that target high unmet medical needs arising from the complications of hypoxia (oxygen deprivation). We seek to make these treatments available to patients across the globe, including emerging economies.

    Home – Slogan
  • Module: CTA 2

    Meet LEAF-4L6715

    Our lead asset, LEAF-4L6715, a novel liposomal formulation of transcrocetin, is designed to enhance oxygen diffusion in plasma and interstitium to address hypoxia-related disorders.

  • Clinical Trials

    LEAF-4L6715 Is being studied in three Phase 3 registrational studies in Europe: Acute Respiratory Distress Syndrome (ARDS), Glioblastoma, and Sarcoma.

    Module: CTA 2
  • Module: CTA 2

    ARDS

    LEAF-4L6715 received Compassionate Use Authorization in France for ARDS.

Hypoxia is Life Threatening

What is hypoxia and which diseases are implicated?

  • Deprivation

    Hypoxia is the deprivation of adequate oxygen supply in a region of the body, resulting in organ destruction, organ failure, and death

  • Multifactoral

    Hypoxia is multifactorial and an underlying cause of many diseases, responsible for >30M deaths annually
  • Module: Slidable Insights 2

    In ARDS/Sepsis/Respiratory Failure

    Hypoxia damages microcirculation in the endothelium

  • In Cancer

    Hypoxia aids tumor progression and treatment resistance

    Module: Slidable Insights 2
  • Module: Slidable Insights 2

    In Cardiovascular Disease

    Hypoxia kills living tissue

  • In Malaria/Infectious Disease

    Hypoxia compromises oxygen supply

    Module: Slidable Insights 2

ARDS

Acute Respiratory Distress Syndrome (ARDS) is Caused by a Broad Range of Direct and Indirect Lung Injuries

  • ARDS

    Sepsis Related ARDS

    Life-threating medical conditions, main cause of ARDS and is the body’s extreme response to an infection. Responsible for 30% of ICU admissions. Compromised microcirculation is the driver of sepsis and is responsible for multi organ failure and death.

  • ARDS

    COVID-19 Related ARDS

    Severe COVID-19 causes inflammation and fluid in the lungs, leading to ARDS and ultimately hypoxia. ARDS is the major cause of mortality in COVID-19.

  • ARDS

    Other ARDS

    Can be triggered by many diseases and conditions including pneumonia, aspiration, sever chest injury, inhaling harmful substances, blood transfusions.